Letters to the Editor

Pathogenicity of Blastocystis hominis

The letter of J. E. Rosenblatt (6) refutes some published work affirming Blastocystis hominis to be an important agent of intestinal disease in humans. The superb and well-controlled study by Kain et al. is one example of a plethora of sound studies (2). The proportion of affirmative literature on B. hominis pathogenicity to the “anti” literature is approximately 20:1. The two most quoted “anti” articles are basically flawed. A complete bibliography can be found in an upcoming review by me (11).

Unfortunately, the scant criticism in the literature of work on the pathogenicity of this protozoan is based on speculation rather than credible data. I submit that “. . . speculation concerning its pathogenicity,” as stated by Dr. Rosenblatt, might more accurately be stated “. . . speculation concerning its nonpathogenicity.” Dr. Rosenblatt states: “Some patients with diarrhea have the organism in their stool and some do not; some asymptomatic patients have it in their stool and some do not.” What a beautiful description of the presence of Entamoeba histolytica!

In response to Dr. Rosenblatt’s numbered critiques: (i) “Koch’s postulates have never been satisfied. . . .” To invoke Koch’s postulates in this area is unnecessary. At least a dozen articles describing B. hominis epidemics in soldiers and institutions and familial outbreaks, in which transmission followed by symptomatic infection is described, are available.

(ii) “No pathogenic evidence of or immunologic response to ‘infection’ has been demonstrated in humans. . . .” There are many descriptions of gastrointestinal pathology (1–3, 7–10). Immunological aspects are essentially unstudied. Eosinocytosis is frequent.

(iii) “No mechanisms of pathogenicity, such as toxin elaboration, attachment to intestinal mucosa, or invasiveness, in humans have been described. . . .” Here, again, purified-toxin studies have not been reported to date. Employing the isolated ileal segment technique in the rabbit, injection of purified fractions from B. hominis cultures elicits strongly positive fluid response (12). Attachment to or invasion of intestinal mucosa is not a requirement for pathogenicity (as, for example, with Cryptosporidium parvum and Giardia lamblia). However, mucosal invasion in B. hominis infections in gnotobiotic guinea pigs has been recorded (5). As for the requirement for bacterial cohorts for pathogenesis, this is true also of E. histolytica, and this has been in the literature for 35 years (4).

(iv) Dr. Rosenblatt states that “no antimicrobial agent which is uniquely active against B. hominis has been shown to reliably eradicate both the organism and the diarrhea. . . .” Emetine is very effective against blastocystosis but must be used in the hospital because of possible toxicity. The arsenicals Stovarsol (acetarsone) and Narsol are also very effective and are approved for use. References to use of the various drugs are too numerous to list here. In recent years, metronidazole has been used most and is usually effective, although there is indication of resistant strains of B. hominis. Trimethoprim-sulfamethoxazole is effective, and Floraquin (diodohydroxyquinoline) is moderately effective.

(v) “There has never been a point-source outbreak of gastroenteritis in which epidemiologic evidence suggested that B. hominis was the cause.” Dr. Rosenblatt seems to believe that all intestinal protozoa must fit the mold of some archetypical pathogen. Unfortunately, there is no such model against which all others are measured. Diversity is the hallmark of pathogenic protozoa. But there will probably be “point-source” outbreaks reported as more studies are done. The many military and institutional outbreaks reported had a source, even though it was too convoluted to discern.

One might comment that the Comte de Buffon and John Needham have been dead for over 200 years, and Felix Pouchet for over 100 years, but their spirit lives on.

REFERENCES

Charles H. Zierdt
Microbiology Service
Clinical Pathology Department
National Institutes of Health
Bethesda, Maryland 20892

Author’s Reply

I do not believe the disagreement over the scientific evidence for the pathogenicity of Blastocystis hominis will be settled in the letters section, and I am reluctant to contribute further to this dispute. However, having been given the opportunity to respond to Dr. Zierdt’s letter, I will do so. Of course, those interested in this area will recognize that Dr. Zierdt has long been a proponent of the pathogenicity of B. hominis theory. I am simply a detached observer.
Genetic Heterogeneity in Strains of *Pseudomonas aeruginosa* from Patients with Cystic Fibrosis

The article by Hjelm et al. (2) contains interesting observations. However, we question the authors’ interpretation of data published previously by our group and others regarding the number of strains of *Pseudomonas aeruginosa* present in patients with cystic fibrosis (CF) and the genetic events related to the changes in the restriction patterns reported by Hjelm et al. in their studies.

The authors state: "Ogle et al. . . . and Pasloske et al. . . ., using separate DNA probes to test restriction fragment length polymorphisms (RFLPs) within serial isolates of *P. aeruginosa* from cystic fibrosis patients, demonstrate that cystic fibrosis patients are infected by only one strain of *P. aeruginosa*, which displays many different phenotypes." Although CF patients are usually infected with only one
We noted with interest the letters by Rosenblatt (4) and Zierdt (6) concerning the possible pathogenicity of Blastocystis hominis. This discussion is particularly exciting to the microscopist, as B. hominis is probably the second most frequently identified organism (yeasts being the first) in the gut flora. We are concerned that all laboratories are not dealing with the same set of "facts" concerning B. hominis since reports on its prevalence have varied from 0 (5) to 3.2 (2) to 17.5 (3)%. This may be due in part to differing proficiencies of technologists at recognizing the organism.

When B. hominis was first defined (as an artifact or yeast), the abilities of laboratories to recognize it varied greatly. B. hominis was frequently included in the artifact section of atlases (1), was never included on proficiency tests, and was hardly ever reported. In recent years it has been included, initially as an optional and then as a required organism, in CAP and other state and national survey samples. The recent review by Zierdt (7), however, may be the first publication of extensive high-quality photographs of the organism in its various forms and stages. In our experience it is difficult for the untrained microscopist to identify B. hominis with the simple hematology microscope frequently employed for parasite examinations. The frequency of identification improves dramatically when a microscope with high quality optics is employed. Since the organisms lack a cell wall and the cytoplasm is frequently condensed around the periphery, we employ phase-contrast optics as part of every examination. Additionally, we examine all specimens with a trichrome procedure and have found this stain to be excellent for recognition of B. hominis.

Using these procedures we have identified B. hominis with great frequency. At Meadowlands Clinical Laboratory (Rutherford, N.J.), we found an almost 20% positive rate. At Great Smokies Diagnostic Laboratory we found a 15 to 20% positive rate. As both labs are reference laboratories, receiving most of their specimens from patients visiting physician offices, the prevailing complaints are more chronic than acute. In a separate study of patients with acute gastrointestinal complaints from a largely immigrant population (62% Latin American and 23% Asian) visiting the outpatient GI Clinic of Elmhurst Hospital (Bronx, N.Y.), we observed a positive rate of Blastocystis identification of 60% (42 of 70 patients). Trichrome smears were reread at the Centers for Disease Control in Atlanta, Georgia (100% agreement), confirming the accuracy of our observations. It appears to us that this organism is very prevalent in stool samples from both acutely and chronically ill patients and that a need for improved training programs probably exists. We believe that independent of the status of this organism's pathogenicity, its presence should always be reported. Only then will physicians and researchers have the data on which to draw conclusions concerning the organism's medical significance.

As for the question of pathogenicity, we believe that a certain confusion exists with respect to the possible involvement of this organism in chronic compared with acute illnesses. In the case of acute illness, it is important to be able to identify a unique cause and to be able to direct therapy against this cause. The case for pathogenicity of B. hominis in acute illness, although mostly based upon epidemiological evidence, is fairly strong but not conclusive. Clearly, the dialogue and debate are not over. The case for pathogenicity of B. hominis in chronic illness, however, is more complex. We frequently observe B. hominis in patients with diminished levels of Escherichia coli and/or Lactobacillus spp., with high fecal pH values, with low butyrate values, and/or with an overgrowth of Candida spp. These patients often have prolonged transit times and have assorted gastrointestinal complaints, together with a myriad of other complicating symptoms. We suspect that in these patients B. hominis may have a real but weak pathogenicity, contributing to illness as part of a larger picture, including nutritional and digestive components.

REFERENCES

Martin J. Lee
Great Smokies Diagnostic Laboratory
18A Regent Park Boulevard
Asheville, North Carolina 28806

Ed. Note: Dr. Zierdt felt that no response was necessary.

Medical Wire and Equipment Company Microring YT

A study by Shankland et al. (1) was based on a product that was manufactured by Mast Laboratories, Liverpool, United Kingdom, not by Medical Wire and Equipment Company (MW&E). MW&E had contracted Mast Laboratories in 1987 to make the Microring YT. Because of the poor performance of the Mast-manufactured product, which was the product used in the above-referenced article, MW&E severed its manufacturing agreement with Mast Laboratories in 1988. MW&E immediately proceeded to research, develop, and manufacture this product in-house. In May 1990, at the American Society for Microbiology Annual Meeting in Anaheim, Calif., a poster session was presented